文献速递眼底病与葡萄膜炎

光激活病毒样药物偶联物治疗结膜黑色素瘤细胞系诱导免疫原性细胞死亡

Treatment of Conjunctival Melanoma Cell Lines With a Light-Activated Virus-Like Drug Conjugate Induces Immunogenic Cell Death.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

本研究使用三种人结膜黑色素瘤(CJM)细胞系,检测光激活病毒样药物偶联物Bel-sar的亚细胞定位、细胞毒性和损伤相关分子模式(DAMP)暴露及巨噬细胞吞噬作用。Bel-sar被CJM细胞内化并定位于细胞膜、溶酶体、高尔基体和线粒体,光激活后诱导接近完全细胞死亡(IC50 30-60 pM),增强钙网蛋白和热休克蛋白90暴露并刺激巨噬细胞吞噬。作者认为Bel-sar通过直接杀伤和免疫刺激双重机制成为CJM潜在治疗手段。

要点

  • Bel-sar被三种CJM细胞系结合并内化,定位于细胞膜、溶酶体、高尔基体和线粒体。
  • 光激活Bel-sar诱导接近完全细胞死亡,IC50值为30 pM至60 pM。
  • 光激活Bel-sar增强DAMP(钙网蛋白、热休克蛋白90)暴露并刺激巨噬细胞吞噬。

核心结论

  • 光激活Bel-sar在全部三种CJM细胞系中诱导促免疫原性细胞死亡,伴随DAMP暴露,提示其通过双重机制成为CJM潜在治疗手段。

研究设计与样本

  • 体外研究,使用三种人肿瘤来源的结膜黑色素瘤(CJM)细胞系。
  • 用示踪剂确定Bel-sar的亚细胞和细胞内定位。
  • 光激活Bel-sar后评估细胞毒性和损伤相关分子模式(DAMP)暴露。
  • 将处理后的肿瘤细胞与THP-1来源巨噬细胞共培养以评估肿瘤细胞吞噬作用。

主要发现

  • Bel-sar被CJM细胞结合并内化,随后见于细胞膜、溶酶体、高尔基体和线粒体。
  • Bel-sar激活诱导接近完全细胞死亡,半数抑制浓度(IC50)值在30 pM至60 pM之间。
  • 光激活Bel-sar增强DAMP暴露,包括钙网蛋白、热休克蛋白90,并刺激巨噬细胞吞噬作用。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Conjunctival melanoma (CJM) is a rare malignant ocular surface tumor, which often leads to local recurrences and metastases. In murine models of subcutaneous tumors, treatment with a novel virus-like drug conjugate (VDC; Bel-sar) showed a dual mechanism of action with direct tumor cell killing as well as stimulation of an antitumoral immune response. Bel-sar is currently being evaluated for the treatment of primary uveal melanoma and indeterminate nevi in a phase III clinical trial. We determined whether Bel-sar also has direct antitumor efficiency and a potential immunostimulatory capacity in CJM cells. METHODS: Three human tumor-derived CJM lines were used. Bel-sar's subcellular and intracellular locations were determined with tracers. Following light activation of Bel-sar, cytotoxicity and exposure of damage-associated molecular patterns (DAMPs) were assessed. Treated tumor cells were co-cultured with THP-1 derived macrophages to assess tumor-cell phagocytosis. RESULTS: Bel-sar was bound and internalized by CJM cells and subsequently found in the cell membrane, lysosome, Golgi apparatus, and mitochondria. Bel-sar activation induced near complete cell death with half-maximal inhibitory concentration (IC50) values between 30 pM and 60 pM. Finally, light-activated Bel-sar enhanced exposure of DAMPs, including calreticulin, heat shock protein 90, and stimulated phagocytosis by macrophages. CONCLUSIONS: Treatment with a novel VDC (Bel-sar) induced pro-immunogenic cell death in all three CJM cell lines. The in vitro cytotoxicity was accompanied by exposure of DAMPs, suggesting Bel-sar is a potential treatment for CJM by a dual mechanism of action. This dual mechanism may provide a targeted and direct killing of tumor cells and induce an immune response which might decrease local recurrences and metastasis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ma S, Huis In't Veld RV, de Los Pinos E, et al. Treatment of Conjunctival Melanoma Cell Lines With a Light-Activated Virus-Like Drug Conjugate Induces Immunogenic Cell Death. Invest Ophthalmol Vis Sci. 2024. PMID: 39495183. doi:10.1167/iovs.65.13.3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。